French drug major Sanofi (Euronext: SAN) on Friday said it has signed a collaboration and license agreement with Lexicon Pharmaceuticals (Nasdaq: LXRX) worth an upfront payment of $300 million to develop and market sotagliflozin, a drug candidate to treat diabetes.
Under the terms of the agreement, Lexicon is also eligible to receive development, regulatory and sales milestone payments of up to $1.4 billion. Lexicon is also entitled to tiered, escalating double digit percentage royalties of net sales of sotagliflozin. In return, Sanofi will get the exclusive worldwide license to develop, manufacture and commercialize sotagliflozin.
Pascale Witz, executive vice president, Sanofi, said: "This agreement with Lexicon reinforces our commitment to helping people living with diabetes. Adding sotagliflozin to our portfolio, which includes medicines at virtually every stage of the treatment pathway, highlights our focus on providing a large and diverse set of therapeutic options for people with this disease."
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze